Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Drug Dev ; 9(7): 805-812, 2020 10.
Article in English | MEDLINE | ID: mdl-32196954

ABSTRACT

Levocetirizine is classified as a second-generation antihistamine. Levocetirizine is available for the treatment of allergic disorders such as allergic rhinitis and chronic idiopathic urticaria. This was a single-center, single-dose, open-label, randomized, 2-way crossover study in healthy Japanese male subjects consisting of 2 parts. Part 1 compared the bioavailability of levocetirizine oral disintegrating tablet (ODT) and levocetirizine immediate-release tablet (IRT) taken with water in the fasted state in 24 subjects; all subjects completed this part of the trial. In part 2, the bioavailability of levocetirizine ODT without water was compared with that of levocetirizine IRT with water in the fasted state in 48 subjects; 47 subjects completed this part of the trial. Bioequivalence was demonstrated between levocetirizine IRT 5 mg and ODT 5 mg. The safety profiles were generally similar between levocetirizine ODT and levocetirizine IRT, with no serious adverse events, deaths, or adverse events leading to withdrawal reported during the study.


Subject(s)
Cetirizine/pharmacokinetics , Chronic Urticaria/drug therapy , Histamine H1 Antagonists, Non-Sedating/pharmacokinetics , Rhinitis, Allergic/drug therapy , Administration, Oral , Adult , Cetirizine/administration & dosage , Cetirizine/adverse effects , Cross-Over Studies , Drug Compounding/trends , Healthy Volunteers , Histamine H1 Antagonists, Non-Sedating/administration & dosage , Histamine H1 Antagonists, Non-Sedating/adverse effects , Humans , Japan , Male , Middle Aged , Safety , Therapeutic Equivalency
SELECTION OF CITATIONS
SEARCH DETAIL
...